226 related articles for article (PubMed ID: 16791713)
1. Acute myocardial infarction during high-dose methylprednisolone therapy for Graves' ophthalmopathy.
Owecki M; Sowiński J
Pharm World Sci; 2006 Apr; 28(2):73-5. PubMed ID: 16791713
[TBL] [Abstract][Full Text] [Related]
2. Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.
Moleti M; Giuffrida G; Sturniolo G; Squadrito G; Campennì A; Morelli S; Puxeddu E; Sisti E; Trimarchi F; Vermiglio F; Marinò M
Endocrine; 2016 Oct; 54(1):259-268. PubMed ID: 27003434
[TBL] [Abstract][Full Text] [Related]
3. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy.
Zhu W; Ye L; Shen L; Jiao Q; Huang F; Han R; Zhang X; Wang S; Wang W; Ning G
J Clin Endocrinol Metab; 2014 Jun; 99(6):1999-2007. PubMed ID: 24606088
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular and cerebrovascular events in temporal relationship to intravenous glucocorticoid pulse therapy in patients with severe endocrine ophthalmopathy.
Lendorf ME; Rasmussen AK; Fledelius HC; Feldt-Rasmussen U
Thyroid; 2009 Dec; 19(12):1431-2. PubMed ID: 19895339
[No Abstract] [Full Text] [Related]
6. Hypokalemic paralysis following administration of intravenous methylprednisolone in a patient with Graves' thyrotoxicosis and ophthalmopathy.
Tigas S; Papachilleos P; Ligkros N; Andrikoula M; Tsatsoulis A
Hormones (Athens); 2011; 10(4):313-6. PubMed ID: 22281888
[TBL] [Abstract][Full Text] [Related]
7. [Steroid therapy for Graves' ophthalmopathy].
Hiromatsu Y
Nihon Rinsho; 2006 Dec; 64(12):2279-85. PubMed ID: 17154092
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy.
Aktaran S; Akarsu E; Erbağci I; Araz M; Okumuş S; Kartal M
Int J Clin Pract; 2007 Jan; 61(1):45-51. PubMed ID: 16889639
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the patients with Grave's ophthalmopathy after the corticosteroids treatment.
Petrović MJ; Sarenac T; Srećković S; Petrović M; Vulović D; Janićijević K
Vojnosanit Pregl; 2012 Mar; 69(3):249-52. PubMed ID: 22624411
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of methylprednisolone pulse therapy for Graves' ophthalmopathy.
Gao G; Dai J; Qian Y; Ma F
Clin Exp Ophthalmol; 2014 Nov; 42(8):769-77. PubMed ID: 24617953
[TBL] [Abstract][Full Text] [Related]
11. Overall safety and efficacy of high-dose and low-dose intravenous glucocorticoid therapy in patients with moderate-to-severe active Graves' ophthalmopathy.
Ueda-Sakane Y; Kanamoto N; Fushimi Y; Tanaka-Mizuno S; Yasuno S; Miura M; Sone M; Yasoda A; Okada T; Togashi K; Nakao K; Inagaki N
Endocr J; 2016 Aug; 63(8):703-14. PubMed ID: 27263854
[TBL] [Abstract][Full Text] [Related]
12. The influence of Graves' orbitopathy treatment with intravenous glucocorticoids on adrenal function.
Ambroziak U; Bluszcz G; Bednarczuk T; Miśkiewicz P
Endokrynol Pol; 2017; 68(4):430-433. PubMed ID: 28604944
[TBL] [Abstract][Full Text] [Related]
13. Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.
Miskiewicz P; Milczarek-Banach J; Bednarczuk T; Opolski G; Glowczynska R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261581
[TBL] [Abstract][Full Text] [Related]
14. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
Wiersinga WM
Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
[TBL] [Abstract][Full Text] [Related]
15. Adrenal reserve following treatment of Graves' orbitopathy with intravenous glucocorticoids.
Giotaki Z; Fountas A; Tsirouki T; Bargiota A; Tigas S; Tsatsoulis A
Thyroid; 2015 Apr; 25(4):462-3. PubMed ID: 25602127
[No Abstract] [Full Text] [Related]
16. [Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids].
Brauer VF; Scholz GH
Med Klin (Munich); 2004 Feb; 99(2):71-6. PubMed ID: 14963657
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of combined parenteral and oral steroid therapy in Graves' orbitopathy.
Nedeljkovic Beleslin B; Ciric J; Zarkovic M; Stojkovic M; Savic S; Knezevic M; Stankovic B; Trbojevic B
Hormones (Athens); 2014; 13(2):222-8. PubMed ID: 24776622
[TBL] [Abstract][Full Text] [Related]
19. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association.
Marcocci C; Watt T; Altea MA; Rasmussen AK; Feldt-Rasmussen U; Orgiazzi J; Bartalena L;
Eur J Endocrinol; 2012 Feb; 166(2):247-53. PubMed ID: 22058081
[TBL] [Abstract][Full Text] [Related]
20. Smoking was associated with poor response to intravenous steroids therapy in Graves' ophthalmopathy.
Xing L; Ye L; Zhu W; Shen L; Huang F; Jiao Q; Zhou X; Wang S; Wang W; Ning G
Br J Ophthalmol; 2015 Dec; 99(12):1686-91. PubMed ID: 26061160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
